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FBI-1 (Pokemon/ZBTB7A) is a proto-oncogenic transcrip-
tion factor of the BTB/POZ (bric-a`-brac, tramtrack, and
broad complex and pox virus zinc finger) domain family.
Recent evidence suggested that FBI-1 might be involved in
adipogenic gene expression. Coincidentally, expression of
FBI-1 and fatty-acid synthase (FASN) genes are often
increased in cancer and immortalized cells. Both FBI-1 and
FASN are important in cancer cell proliferation. SREBP-1 is a
major regulator of many adipogenic genes, and FBI-1 and
SREBP-1 (sterol-responsive element (SRE)-binding protein
1) interact with each other directly via their DNA binding
domains. FBI-1 enhanced the transcriptional activation of
SREBP-1 on responsive promoters, pGL2–6x(SRE)-Luc and
FASN gene. FBI-1 and SREBP-1 synergistically activate tran-
scription of the FASN gene by acting on the proximal GC-box
and SRE/E-box. FBI-1, Sp1, and SREBP-1 can bind to all three
SRE, GC-box, and SRE/E-box. Binding competition among
the three transcription factors on the GC-box and SRE/E-box
appears important in the transcription regulation. FBI-1 is
apparently changing the binding pattern of Sp1 and SREBP-1
on the two elements in the presence of induced SREBP-1 and
drives more Sp1 binding to the proximal promoter with less
of an effect on SREBP-1 binding. The changes induced by
FBI-1 appear critical in the synergistic transcription activa-
tion. The molecular mechanism revealed provides insight
into how proto-oncogene FBI-1 may attack the cellular regu-
latory mechanism of FASN gene expression to provide more
phospholipid membrane components needed for rapid can-
cer cell proliferation.
FBI-1 (factor that binds to the inducer of short transcripts of
human immunodeficiency virus-1, also called Pokemon,
ZBTB7A) is a member of the BTB/POZ domain class of tran-
scription regulatory proteins (1–2). It was originally isolated as
a cellular factor that binds to the inducer of short transcripts of
human immunodeficiency virus-1 and the proximal GC-rich
sequence of ADH5/FDH (ADH5/FDH is alcohol dehydrogen-
ase 5/formaldehyde dehydrogenase) (3, 4). Molecular cloning
revealed that FBI-1 is a transcription factor with a POZ domain
at the N terminus and Kru¨ppel-type four C2H2 zinc fingers at
the C terminus (4, 5), and Western blot analysis showed that
FBI-1 is a 75-kDa protein. FBI-1 has been shown to have variety
of biological functions such as human immunodeficiency virus
type 1 Tat trans-activation, stimulation of NF-B activity,
potential role in adipogenesis, osteoclastogenesis, B-cell lym-
phoma, and repression of ADH5/FDH gene transcription (4,
6–10). Serial analysis of gene expression analysis revealed that
expression of FBI-1 is increased inmultiple cancers (available at
www.ncbi.nlm.nih.gov). Recently, FBI-1 was shown to cause
cancer in the thymus, liver, and spleen by repressing the tumor
suppressor gene ARF that in turn lowers the expression of
another tumor suppressor p53 gene (11). Also, mouse FBI-1
(called LRF) was shown to regulate B versusT lymphoid lineage
fate decisions (12).
SREBPs3 are bHLH leucine zipper family transcription fac-
tors and are themajor regulators of transcription of chorestero-
genic and lipogenic genes (13, 14). There are three isoforms
of SREBPs as follows: SREBP-1a, SREBP-1c, and SREBP-2.
SREBP-1a and SREBP-1c are transcribed from the same
SREBP-1 gene, each by a distinct promoter. The two SREBP-1
proteins are identical except the extreme N termini. SREBP-1a
has 28 unique amino acids from its first exon and SREBP-1c has
only four (in addition to the initiator Methionine). SREBP-2 is* This work was supported by a Korea Research Foundation Grant E00046
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encoded by the separate gene SREBP-2 that encodes a single
mRNA (15, 16 and references therein).
The relative levels of SREBP-1a and -1c mRNA were
shown to vary over the 50–100-fold range in different tis-
sues. The predominant isoform in adult liver and adipocytes
is SREBP-1c, so it may be the key protein involved in SREBP-
1-dependent processes in these tissues. SREBP-1a is also the
predominant form in spleen and in all cultured cells, includ-
ing cancer cells (17). It is possible that the more active
SREBP-1a isoform is preferentially expressed to meet the
cellular need for more cholesterol and fatty acids during
periods of rapid cell proliferation.
SREBP-1a has a potent activation domain in the N-terminal
region, which interacts efficiently with co-activators such as
p300/CREB-binding protein (18), Sp1 (19, 20), and the mam-
malian mediator complex (21). The shorter N terminus of
SREBP-1c is a weak activation domain and interacts weakly
with the same transcriptional co-activators. SREBP-1a is a
potent transcription activator of all SREBP-responsive genes,
including those that mediate the synthesis of cholesterol, fatty
acids, and triglycerides. SREBP-1c, with its weak and short
N-terminal transcription activation domain, preferentially
enhances transcription of genes required for fatty acid synthesis
but not cholesterol synthesis. SREBP-2 preferentially activates
cholesterol synthesis (15, 16 and references therein).
One of the key metabolic enzymes of which expression is
controlled by SREBP-1 is fatty-acid synthase (FASN) (16).
FASN catalyzes the condensation of malonyl-CoA and acetyl-
CoA to produce the 16-carbon fatty acid palmitate (22). The
expression of FASN is very low in almost all nonmalignant adult
tissues but is highly expressed in many cancer types (17). Can-
cer cells show increased de novo fatty acid synthesis, and in fact,
FASN is the only enzyme capable of fatty acid synthesis inmost
carcinomas (23–25 and references therein). Although FASN is
active in cancer cells, as in liver and other lipogenic tissues, the
fate of the palmitate differs between cancer cells and lipogenic
tissues. In liver and adipose tissue, fatty acid synthesis occurs to
store excess calories from carbohydrate as triglyceride. But
most human cancers do not store significant amounts of trig-
lyceride. Endogenously synthesized fatty acids in cancer cells
are esterified to phospholipids to supply membrane compo-
nents of rapidly proliferating cancer cells (26, 27).
It is important to investigate how the FASN gene is regulated
not only in the normal cellular context but also in the context of
cancer cells. The transcriptional regulatory network of FASN
gene expression under various physiological conditions is com-
plex and involves multiple transcription factors. Transcription
factor-wise, specificity proteins 1 and 3 (Sp1 and Sp3), nuclear
factor Y (NF-Y), upstream stimulatory factor, retinoic X recep-
tor, liver X receptor, and sterol regulatory element-binding
protein-1 (SREBP-1) have binding sites on the promoter of the
FASN gene (28 and references therein). Among them, the
SREBP-1 and Sp1 are major regulators acting on the proximal
promoter and activate transcription synergistically by binding
to the SRE (or SRE/E-box) and GC box, respectively (29–34).
They interact with each other, and the interaction was sug-
gested to be important in synergistic transcription activation of
the FASN gene. Accordingly, other proteins interacting either
with SREBP-1 or Sp1 are probably important in the transcrip-
tional regulation of the genes involved in lipid biosynthesis
(29–33). We recently found that FBI-1 interacts with both
SREBP-1 and Sp1 and that FBI-1 modulates the transcriptional
activation by Sp1 (4).
FBI-1 appears to be involved in cell proliferation, preadipo-
cyte differentiation, and adipogenesis (8, 11). The expression of
the FBI-1 is gradually increased up to 2 days after the induction
of adipocyte differentiation in 3T3L1 cells, and its expression
then decreasesmarkedly thereafter. Also, FBI-1 overexpression
in 3T3-L1 cells results in more lipid accumulation during dif-
ferentiation as well. Based on these observations, it was sug-
gested that FBI-1 may be important for adipocyte differentia-
tion where it may activate expression of adipogenic genes,
including FASN (8).
In addition, others recently found that FBI-1 stimulates cell
proliferation and is a potent proto-oncogene (11). We sus-
pected that the proto-oncogene FBI-1may increase FASN gene
expression in cancer cells and thereby provide phospholipid
cell membrane components to meet the lipid needs of rapidly
proliferating cancer cells. In this study, we show that themolec-
ular interactions involving Sp1, SREBP, proto-oncogene FBI-1,
and proximal promoter DNA elements are important in the
transcription activation of the FASN gene that occurs in many
cancer cell types. The datamay have significant implications for
understanding how proto-oncogene FBI-1 plays a role in lipid
biosynthesis and cell proliferation during adipogenesis as well
as oncogenesis.
EXPERIMENTAL PROCEDURES
Plasmids, Antibodies, and Reagents—Fatty-acid synthase
promoter-luciferase reporter genes, pGL2-FASN1-Luc (bp
150/65), pGL2-FASN2-Luc (bp 135/65), and pGL2-
FASN3-Luc (bp 150/73), are reported elsewhere (34).
pGL2–6x (SRE)-tk*-Luc reporter plasmid was prepared by
cloning six copies of the SREBP-responsive element (SRE, only
top strand shown, 5-AAAATCACCCCACTGCAA-3) of the
LDLR gene in front of tk* minimal promoter (35). The two
Sp1-binding element of the tk promoter were mutated to pre-
pare tk* minimal promoter using site-directed mutagenesis kit
(Stratagene, La Jolla, CA).
The pcDNA3.1-SREBP-1a, pcDNA3.1-SREBP-1a-acidicbHLH
(aa 1–394), pcDNA3.1-SREBP-1a-acidicPro/Ser (aa 1–178),
and pcDNA3.1-SREBP-1a-bHLH (aa 337–374) plasmids were
prepared by cloning amplified cDNA fragments from pCMV-
SREBP-1a into the pcDNA3.1 plasmid (Invitrogen). The fol-
lowing oligonucleotide PCR primers were used: SREBP-1a
acidicbHLH (aa 1–394), forward, 5-GATCGGATCCGAC-
GAGCCACCCTTCAGCGA-3, and reverse 5-GATCCTCG-
AGGCTTTTGTGGACAGCAGTGC-3; SREBP-1a-acidic
Pro/Ser (aa 1–178), forward, 5-GATCGGATCCGACGAGC-
CACCCTTCAGCGA-3, and reverse, 5-GATCCTCGAGGG-
GAGGGCTTCCTGTAGAGA-3; SREBP-1a-bHLH (aa 337–
374), forward, 5-GARCGGATCCGAGAAGCGCACAGCCC-
ACAA-3, and reverse, 5-GATCCTCGAGGCTTTTGTGGA-
CAGCAGTGC-3.
To prepare the recombinant GST-bHLHREBP-1 fusion pro-
tein expression vector, the pCMV-SREBP-1a-bHLH (aa 337–
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374) was cloned into pGEX4T3 vector/BamH-Xho (Amer-
sham Biosciences). The oligonucleotide PCR primers used for
bHLHSREBP-1 are forward, 5-GATCGGATCCGCCCCGG-
CCTCTGCCCAGAGC-3, and reverse, 5-GATCCTCGAG-
TCACAGAGATTTGCTTTTGTGGACAG-3.
The recombinant GST fusion protein expression vector for
FBI-1ZFDBD (zinc finger DNA binding domain) (aa 366–495)
was prepared by cloning PCR-amplified cDNA fragments into
pGEX4T1/BamH-Sal. The oligonucleotide PCRprimers used
for FBI-1ZFDBD are forward, 5-GATCGGATCCGCCTGGT-
CGCAGAAGGTGGAG-3, and reverse, 5-GATCGT-
CGACCGAGGGGACGCCGTTGCAGCCGTC-3.
To prepare various truncated FBI-1 mammalian expression
vectors, pcDNA3.0-FLAG-FBI-1, pcDNA3.1-POZNLSFBI-1 (aa
1–131), pcDNA3.0-ZFDBDFBI-1 (aa 371–512), pcDNA3.0-
POZ FBI-1 (aa 132–584), and pcDNA3.0-ZFDBD-C-term (aa
376–584), PCR-amplified cDNA fragments were cloned into
pcDNA3 series mammalian expression vectors, and some were
reported elsewhere (Invitrogen) (4, 7). The PCR oligonucleotide
primersused for theC-terminal (aa376–584)andzinc fingerDBD
of FBI-1 (aa 376–505) are as follows: C-terminal forward, 5-GG-
ATCGAATTCACCATGGACTACAAGGACGACGATGACA-
AGATCCGAGCCAAGGCCTTC-3, and reverse, 5-GGATCT-
CTAGATCATTAGGCGAGTCCGGCTGT-3; ZFDBD of
FBI-1, forward the same as above and reverse 5-GGATCTCT-
AGATCAGCCCCGGACGCGGGGCTT-3.
Antibodies against SREBP-1, FLAG tag, or control IgG were
purchased from Santa Cruz Biotechnology, Upstate (Char-
lottesville, VA), Cell Signaling, Calbiochem, and Sigma. Anti-
body against FBI-1 was prepared by us. Most of the chemical
reagents were purchased from Sigma.
RT-PCR Analysis of mRNA of FBI-1, SREBP, FASN, Sp1,
GAPDH in C57Bl/6J Mice, ob/ob C57Bl/6J Mice, DIO C57Bl/6J
Mice, 293Trex, HCT116, and Prostate LNCaP Cells—Male
C57BL/6J mice were fed either with high fat chow D12492 or
control lean chow (ResearchDiets Inc., NewBrunswick, NJ) for
20 weeks to generate diet-induced obese mice (DIO). Total
RNAwas isolated fromhumanHEK293T cells, human prostate
LNCaP cells, and the abdominal adipose tissues of control and
obese ob/ob C57Bl/6J mice or DIO mice using TRIzol reagent
(Invitrogen). cDNAs were synthesized using 1g of total RNA,
random hexamer (10 pmol), and Superscript reverse tran-
scriptase II (200 units) in 20 l using reverse transcription kit
(Invitrogen). PCR were performed by using the following
amplification conditions: 94 °C denaturation for 5 min, 35
cycles of amplification reaction, 94 °C for 1 min, 60 °C for 45 s,
72 °C for 1.5 min, and final extension reaction at 72 °C for 10
min. Oligonucleotide primers used for PCR are as follows:
FBI-1 (LRF-1), forward, 5-GCCTGGCTGTGCGACGTGGT-
3, and reverse, 5-CAGCAGGCGGGCGGCGCTGA-3;
SREBP-1, forward, 5-GATCGGATCCGAGAAGCGCACA-
GCCCACAA-3, and reverse 5-GATCCTCGAGGCTTTT-
GTGGACAGCAGTGC-3; FASN, forward, 5-GATCGAA-
TTCAACCATGGAGGAGGTGGTGATAGCCGGT-3, and
reverse, 5-GATCCTCGAGTGCCAGCAAGCTGGAGGAG-
CAGGC-3; Sp1, forward, 5-CGTGGATCCACAGGTGAGC-
TTGACCTCACAGC-3, and reverse, 5-CGTGCGGCCGCC-
TATATGATCTGTATTTGACCAG-3; and GAPDH, forward,
5-ATGGGGAAGGTGAAGGTCGGAGTC-3, and reverse,
5-TTACTCCTTGGAGGCCATGTGGGC-3.
Western Blot Analysis of FBI-1, SREBP, FASN, GAPDH in
293Trex, HCT116, and Prostate LNCaP Cells—Cells were har-
vested and lysed in RIPA buffer (50 mM Tris-HCl, pH 8.0, 1%
Nonidet P-40, 0.25% sodium deoxycholic acid, 150 mMNaCl, 1
mM EGTA, Complete Mini-Protease mixture). Cell extracts
(25–50 g) were separated using 8–12% gradient SDS-PAGE,
transferred onto Immun-BlotTM polyvinylidene difluoride
Membrane (Bio-Rad), and blocked with 5% skimmilk (BD Bio-
sciences). Blotted membranes were incubated with antibodies
against FLAG tag (Sigma), FBI-1 (Abcam, Cambridge, UK),
GAPDH (Chemicon, CA), SREBP-1 (Santa Cruz Biotechnol-
ogy), FASN (prepared by us), His tag, and Myc tag (Santa Cruz
Biotechnology) and then incubated with horseradish peroxi-
dase-conjugated mouse, rabbit, or goat IgG (Vector Laborato-
ries). Protein bands were visualized with ECL solution
(PerkinElmer Life Sciences).
Cell Culture and Transcriptional Analysis of the SREBP-re-
sponsive pGL2–6x(SRE)-Luc Promoter by SREBP-1 and FBI-1
by Transient Transfection—Human liver Alexander, human
kidney HEK293A, human colon HCT116, mouse embryonic
NIH/3T3, and African green monkey kidney CV-1 cells were
cultured in the medium recommended by the ATCC (Manas-
sas, VA) and supplemented with 10–15% fetal bovine serum
(Invitrogen). The cells were seeded onto 6-well plates and
grown for 16 h before transfection.
To test the effect of FBI-1 on the transcriptional activation of
the SREBP-1-responsive promoter, the mammalian cells were
transfected with the mixture of 1.1 g of the reporter pGL2–
6x(SRE)-tk*-Luc plasmid (0.2g), pcDNA3-FBI-1 (0.6g), and
pcDNA3 SREBP-1a or -1c (0.025g), using Lipofectamine Plus
reagent (Invitrogen). The cells were harvested 36 h after trans-
fection and lysed, and luciferase activities were analyzed. Lucif-
erase activity was normalizedwith co-transfected-galactosid-
ase activity or the protein concentration of the cell lysates.
To investigate the functional consequences of molecular inter-
action between the SREBP-1 and the ZFDBDFBI-1 on the tran-
scription of pGL2–6x(SRE)-tk*-Luc, the cells (HEK293A orAlex-
ander) were co-transfected with the mixture of 1.1 g of pGL2–
6x(SRE)-tk*-Luc (0.3 g), pcDNA3-FBI-1, or pcDNA3-
ZFDBDFBI-1 (0.6 g) and pcDNA3 SREBP-1a or -1c (0.025 g),
using Lipofectamine Plus reagent (Invitrogen) and analyzed as
described above.
GST Fusion Protein Purification, in Vitro Transcription and
Translation, and GST Fusion Protein Pulldown Assays—The
Escherichia coli BL21 (DE3) transformed with either GST or
GST-bHLHSREBP-1 proteins expression vector (pGEX4T3-
bHLHSREBP-1) was induced with 0.5 mM isopropyl 1-thio--
D-galactopyranoside for 4 h at 37 °C. After E. coli pellets were
lysed and sonicated in lysis buffer (1 PBS, 1 mM phenylmeth-
ylsulfonyl fluoride, 2 mM EDTA, and 0.2 mg/ml lysozyme),
recombinant proteins were purified by affinity chromatogra-
phy using glutathione-agarose 4 beads (Peptron, Daejeon,
Korea). Purified proteins were resolved on a 15% SDS-polyac-
rylamide gel to quantitate and assess purity. The same volume
of protein-agarose bead complex was used for all GST fusion
protein pulldown assays.
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The four full-length and truncated [35S]methionine-labeled
FBI-1 polypeptides were prepared by in vitro transcription and
translation by incubating 1 g of the pcDNA3.0 FBI-1 or its
deletionmutants [pcDNA3.0 POZFBI-1 (aa 1–131), pcDNA3.0
FBI-1POZ (aa 132–584), pcDNA3.0 FBI-1 C-term (aa 376–
584)] expression vectors, 2 l of [35S]methionine (PerkinElmer
Life Sciences), and 40 l of TNT Quick Master Mix (Promega,
WI) at 30 °C for 90 min.
Purified GST fusion proteins were incubated with GSH-aga-
rose at 4 °C for 1 h in HEMG buffer (40mMHEPES, pH 7.9, 100
mM KCl, 0.2 mM EDTA, 5 mM MgCl2, 0.1% Nonidet P-40, 10%
glycerol, 1.5 mM 1,4-dithiothreitol, protease inhibitor mixture
(1 tablet/50 ml)). After agarose-GST protein complexes were
washed, 10 l of in vitro translated FBI-1 proteins were added
and incubated in HEMG buffer at 4 °C for 4 h. The reactions
mixtures were centrifuged, and the pellets were washed, dena-
tured, and separated on a 15%SDS-polyacrylamide gel. The gels
were exposed to x-ray film using an image-intensifying screen
(Eastman Kodak Co.).
Co-immunoprecipitation and Western Blot Analysis—
HEK293A cells were harvested and lysed in lysis buffer (50
mM Tris-HCl, pH 7.5, 0.3 M NaCl, 1% Nonidet P-40, 1 mM
phenylmethylsulfonyl fluoride, and protease inhibitor mix-
ture (1 tablet/50 ml)). Lysates were clarified by centrifuging
at 13,000 rpm for 15 min. 500 g of the lysates were incu-
bated with anti-FBI-1 (or anti-SREBP-1) antibody (2 g) and
subsequently with protein A-agarose (20 l) overnight at
4 °C with gentle rotation. The immunoprecipitates were
washed, denatured, resolved by 15% SDS-PAGE, and trans-
ferred onto Immun-BlotTM polyvinylidene difluoride mem-
brane (Bio-Rad). Blotted membranes were incubated with
following antibodies, Ab-SREBP-1 (or Ab-FBI-1) and Ab-
GAPDH. Membranes were further incubated with horserad-
ish peroxidase-conjugated anti-mouse IgG (Vector Labo-
ratories) or anti-rabbit IgG (Vector Laboratories) and
developed with the ECL reagents (PerkinElmer Life
Sciences).
Immunostaining and Cellular Localization of FBI-1 and
SREBP-1—Human liver Alexander cells were grown on the
coverslips placed in a 6-well culture dish (Sunshine Works,
Seoul, Korea), and the cells were transfected with
pcDNA3.0-FLAG-FBI-1 expression plasmid (0.6 g) and
pcDNA3.1-SREBP-1a-Myc. After 24 h, the cells were washed
with cold PBS and fixed in 97:3 cold methanol/formaldehyde
for 20 min at20 °C. Cells were permeabilized in 0.2% Triton
X-100 and washed with PBS. Next, cells were incubated in 5%
normal horse serum to block nonspecific binding and further
incubated with mouse anti-FLAG primary antibody (0.5
g/100 l) for 2 h at room temperature. The cells were washed
and incubated with fluorescein isothiocyanate-conjugated
anti-mouse IgG secondary antibody (0.5 g/100 l) (Jackson
Laboratories). For double staining, the cells were fixed with
3.7% formaldehyde for 10 min at room temperature, washed,
and blocked with 5% normal horse serum. Washed cells were
incubated with rabbit anti-SREBP-1a antibody and subse-
quently with rhodamine-conjugated anti-rabbit IgG secondary
antibody (0.5 g/100 l). After washing and mounting, immu-
nostained cells were examined with a Carl Zeiss LSM 510 con-
focal laser scanning microscope (Carl Zeiss, Germany).
Transcriptional Analysis of FASN WT or Mt Gene Promoter—
Because FBI-1 activated the transcription of the SREBP-re-
sponsive pGL2–6x(SRE)-tk*-Luc, we investigated whether
FBI-1 can also activate the transcription of the SREBP-1-re-
sponsive FASN gene promoter. Three different FASN gene
promoters, which have short proximal promoter sequences and
are differing only in the context of key proximal regulatory ele-
ments (pGL2-FASN1-Luc, pGL2-FASN2-Luc, and pGL2-
FASN3-Luc), were used in the transcription assays (34). The
mammalian cells (Alexander, HEK293A, HCT116, and
NIH3T3) were transiently transfected with the mixture of 1.1
g of pGL2-FASN-Luc reporter plasmid (e.g. pGL2-FASN1-
Luc, pGL2-FASN2-Luc, and pGL2-FASN3-Luc (0.3 g), and
pcDNA3-FBI-1 (0.025–0.5 g), and pcDNA3 SREBP-1a (0.025
g)) using Lipofectamine Plus reagent (Invitrogen) and ana-
lyzed as described above in the transcription analysis by tran-
sient transfection.
Also transcriptional regulation of FASN gene by SREBP-1
and FBI-1 was analyzed usingmuch longer2.7 kb upstream
regulatory element with either intact WT or mutated SRE/
E-box (bp 65 to 47; WT, 5-TCAGCCCATGTGGCGT-
GGC-3; mutant, 5-TCAGCCTTTGAAGCGTGGC-3).
The mutations were introduced by site-directed mutagene-
sis (Stratagene). The cells were transiently transfected with
the plasmid mixture of pGL2-FASN(2.7 kb)-Luc WT (or
Mt) (0.3 g), pcDNA3.1-SREBP1a expression plasmid (0.025
g), and pcDNA3.1-FBI-1 expression plasmid (0.025–0.5
g) using Lipofectamine Plus reagent (Invitrogen). After
24 h of incubation, cells were harvested and analyzed as
described above.
Electrophoretic Mobility Shift Assay (EMSA)—The oligonu-
cleotide probes (500 pmol each in 83.3 mM Tris-HCl, pH 8.0,
16.7 mM MgCl2, 166.7 mM NaCl) were annealed by heating at
93 °C for 5 min and cooling down slowly to room temperature.
After diluting the solution containing the annealed oligonu-
cleotides with water to 50 mM Tris-HCl, pH 8.0, 10 mMMgCl2,
100 mM NaCl, 100 pmol of annealed oligonucleotides for
EMSAs were labeled with [-32P]ATP and Klenow enzyme
(Roche Applied Science) by incubating for 30 min at 37 °C.
-32P-Labeled double-stranded oligonucleotides were purified
with SephadexTMG-50 (Amersham Biosciences). Sequences of
various oligonucleotides used in EMSA are as follows (only the
top strand is shown): FASN SRE 5-GATCCGGGCATCAC-
CCCACCGACG-3; FASN SRE/E-Box, 5-GATCGTCAGC-
CCATGTGGCGTGGC-3; and FASN GC-box, 5-GATCTG-
GCCGGGCGGCGCAGCCA-3.
Each binding reaction was carried out in 20 l of binding
buffer containing 10 mM HEPES, pH 7.9, 60 mM KCl, 5 M
ZnCl2, 1 mM dithiothreitol, 1% bovine serum albumin, and 7%
glycerol, and purified recombinant His-tagged SREBP (10 ng),
Sp1 (50 ng for GC-box, 150 ng for SRE and SRE/E-box), and
GST-ZFDBDFBI-1 (300 ng). 1.2 g of anti SREBP-1 and Sp1
antibodies (Santa Cruz Biotechnology) and 5 g of anti-GST
antibody (Upstate, Charlottesville, VA)were added to the bind-
ing mixture in some EMSA binding reactions for supershift
assays. The protein-DNA complexes were resolved from free
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probe by 6% nondenaturing PAGE at room temperature in
0.5TBE buffer (89mMTris borate, 2 mM EDTA, pH 8.3). The
dried gels were exposed to x-ray film at 70 °C with a Kodak
intensifying screen (Kodak).
Chromatin Immunoprecipitation (ChIP) Assays—The molec-
ular binding interactions among FBI-1, SREBP-1, Sp1, and
FASN proximal promoter in vivo were analyzed using ChIP
assay kit (Upstate Biotechnology, Inc., Lake Placid, NY) as
reported elsewhere (4). The HEK293A cells grown on a 10-cm
culture dish were transfected with pGL2-FASN2-Luc (or
pGL2-FASN3-Luc, pGL2-FASN-Luc WT or Mt, 2.7 kb) (2
g), pcDNA3.1-SREBP-1a (1g), and pcDNA3-FLAG-FBI-1(3
g) using Lipofectamine Plus. Cells were fixed with formalde-
hyde (final 1%) to cross-link SREBP1 and FBI-1 onto the FASN
promoter. Cells were washed with cold phosphate-buffered
saline and lysedwith SDS lysis buffer (1% SDS, 10mMEDTA, 50
mM Tris-HCl, pH 8.1). The lysate was sonicated to shear DNA
to a length between 500 and 700 bp. The sonicated supernatant
was diluted 10-fold with ChIP dilution buffer (0.01% SDS, 1%
Triton X-100, 2 mM Tris-HCl, pH 8.1, 150 mMNaCl) and incu-
bated with antibodies against FLAG, SREBP1, and Sp1 over-
night at 4 °C with rotation. To collect DNA-protein-antibody
complex, salmon sperm DNA/protein A-agarose slurry was
added to the mixture. The mixture was incubated for 2 h at
room temperature with rotation and collected DNA-protein
A-agarose complex by brief centrifugation (3,000 rpm) at 4 °C.
After extensive washing of the pellet with various washing buff-
ers recommended by themanufacturer, the pellet was dissolved
with 250 l of elution buffer and spun to remove agarose.
Supernatant was treated with 20 l of 5 M NaCl and heated to
65 °C for 2 h to reverse protein-DNA cross-link. After treat-
ment with EDTA and proteinase K, the supernatant was
extracted with phenol/chloroform and precipitated with etha-
nol to recover DNA. PCRs of immunoprecipitated DNA were
carried out using the following oligonucleotide primer sets
designed to amplify the proximal promoter region of the FASN
gene. FASN WT or Mt primers (forward, 5-CAGGCGCGT-
TCCCGCGCAGG-3, and reverse, 5-GAGAGCGAGGCTG-
GAGCGCG-3). For ChIP assays of the shorter FASN2 or -3
promoter constructs, oligonucleotide PCR amplification prim-
ers were designed to bind to the plasmid vector sequences, not
to the endogenous FASN gene promoter: forward, 5-TCCAA-
ACTCATCAATGTA-3, and reverse, 5-AAAGCAATTGTT-
CCAGGAACCAGGG-3.
Knockdown of FBI-1 Expression by siRNA—Two siRNAs
designed to knock down FBI-1 mRNA and a negative control
siRNA were designed and purchased from Bioneer (Daejeon,
Korea) as follows: siFBI-1 426, 5-GCUGGACCUUGUAGAU-
CAAtt-3 and 5-UUGAUCUACAAGGUCCAGCtt-3; siFBI-1
476, 5-AGUACCUCGAGUUCUUCCAtt-3 and 5-UGGAAG-
AACUCGAGGUACUtt-3; and negative control, 5-CCUACGC-
CACCAAUUUCGUtt-3 and 5-ACGAAAUUGGUGGCGUA-
GGtt-3. siRNA (500 pmol of each) were transfected into
HEK293A andHCT116 cells (2 106 cells/6well dishes) by using
Lipofectamine2000 reagent (Invitrogen).After 48h, the cellswere
harvested, and cell lysates were analyzed by Western blot as
described above.
RESULTS
FBI-1 mRNA Expression Is Increased in White Adipose Tis-
sues of ob/ob C57BL/6J Mice and Diet-induced Obese Mice
C57BL/6J—Expression of FBI-1 mRNA increased during the
early stages of adipocyte differentiation in 3T3L1 cells and then
declined as differentiation continued. Also, when 3T3L1 cells
were treated with recombinant adenovirus overexpressing
FBI-1 during differentiation, lipid accumulation as assessed by
Oil RedO staining was significantly enhanced (8). These obser-
vations suggested that FBI-1 might play a role in the adipocyte
differentiation and adipogenesis.
FIGURE 1.The expressionof FBI-1mRNA is increased ingenetically obese
ob/obC57BL/6Jmice andDIOmice. The stable cells overexpressing FBI-1 or
rapid growing LNCaP cells showed increased FASN expression. A, RT-PCR
analysis of FBI-1 mRNA using the total RNA was isolated from the abdominal
adipose tissues of lean control and obese ob/ob C57BL/6J mice. GAPDH, con-
trol. LRF is a murine counterpart of human FBI-1 (also called Pokemon,
ZBTB7A). B, RT-PCR analysis of mRNA of LRF (FBI-1) and SREBP-1 using the
total RNA isolated from the white adipose tissues (WAT) of control and DIO
C57BL/6J mice. Norm, normal; GAPDH, control. C, RT-PCR and Western blot
analysis of FBI-1, SREBP-1, and GAPDH in HEK293Trex control and stable cells
overexpressing FBI-1. The stable cells were induced to express lacZ or FBI-1
gene by doxycycline treatment. Total RNA or protein was isolated from the
cells and analyzed for FBI-1, SREBP-1, and FASN expression at both themRNA
and protein level. GAPDH, control. D, Western blot analysis of human colon
cancer stable HCT116 cells established by transfectionwith lentivirus overex-
pressing either FBI-1 or lacZ. Cell extracts were analyzed for FBI-1, SREBP-1,
and FASN proteins. GAPDH, control. E, RT-PCR and Western blot analysis of
LNCaP cells treated with androgen (Andro) or EtOH. Total RNA or protein was
isolated from the cells and analyzed for FBI-1, SREBP-1, and FASN expression
at both themRNA and protein level.GAPDH, control. F,Western blot analysis.
Knockdownof endogenous FBI-1 decreases FASNgene expression in immor-
talizedHEK293AandHCT116 cancer cells. The cellswere transfectedwith two
independent siRNA against FBI-1 or a control siRNA. The cells were harvested
at 48 h, and the cellular extracts (35g)were analyzed for FASN, FBI-1, SREBP-
1a, and GAPDH expression. NC, negative control.
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FIGURE 2. FBI-1 and SREBP-1a synergistically activate transcription of the pGL2-FASN-Luc via GC-box and SRE/E-box elements in immortalized or
cancer cells. A, nucleotide sequence comparison of threemammalian FASN gene promoters. SRE, upstream SREBP-binding element;GC-box, Sp1-binding GC
box; SRE/E-box, downstream SREBP-binding element; TRE, thyroid hormone-response element; TATA, TBP-binding element; Luc, luciferase. Numbers indicate
the position of nucleotide upstream of transcription initiation (1). B, structures of three FASN-Luc reporter promoter constructs tested to investigate the
functional elementsmediating transcription activation by FBI-1. Tsp, transcription start site (1). C–F, FBI-1 and SREBP-1a synergistically activate transcription
of thepGL2-FASN-Luc viaGC-box andSRE/E-boxelements in themammalian cells co-transfectedwith threedifferent pGL2-FASN-Lucplasmids andexpression
vectors of SREBP-1a (25 ng) and FBI-1 (25 ng, 125 ng, 500 ng). FBI-1 could not activate transcription of the pGL2-FASN3-luc lacking downstream SRE/E-box.
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We evaluated the expression level of LRF (mouse FBI-1)
mRNA in adipose tissue of lean control versus obese ob/ob
C57BL/6J mice to study the possible correlation between fat
mass and LRF expression. RT-PCR analysis of total RNA
showed that LRF mRNA was higher in obese ob/ob mouse as
compared with the lean control
mice (Fig. 1A). We also found that
LRF mRNA was increased in mice
fed with a high fat diet to induce
obesity (DIO) compared with the
lean control, and SREBP-1, which is
a major regulator of fatty acids
synthesis, was also significantly
increased (Fig. 1B).
Increased Expression of FBI-1 and
FASN in HEK293Trex-FBI-1 Stable
Cells and in LNCaP Cells Treated
with Androgen—We investigated
the expression patterns of SREBP-1
and FASN in cells where FBI-1
expression is elevated. In HEK293-
Trex cells overexpressing FBI-1 in
an inducible fashion, FASN was sig-
nificantly increased both at the
mRNA and protein level when
FBI-1 was induced, whereas expres-
sion of SREBP-1 and control
GAPDH remained unchanged (Fig.
1C).We observed similar changes in
protein expression in the colon can-
cer cells HCT116 stably overex-
pressing FBI-1 (Fig. 1D). Prostate
cancer LNCaP cells grew much
faster in the presence of the male
hormone testosterone or androgen.
The mRNAs for FBI-1, SREBP-1,
and FASN were significantly in-
creased in the LNCaP cells treated
with androgen. Immunoblotting
showed similar results for the corre-
sponding proteins (Fig. 1E).
Knockdown of Endogenous FBI-1
Decreases FASN Gene Expression
in Immortalized HEK293A and
HCT116 Cancer Cells—The above
data and transcriptional activity
measurements presented below rely
on overexpressed proteins, and it
may be necessary to provide some
additional evidence for the FBI-1-
SREBP1 interaction in the cells. We
investigated the relationship among
FASN, FBI-1, SREBP-1 in the
immortalized human HEK293A,
andHCT116 colon cancer cells. The
cells were transfected with two
independent siRNA against FBI-1
or a control siRNA. Western blot
analysis of the cell lysates showed that knockdown of FBI-1
expression resulted in significant decrease in FASN expression
(Fig. 1F). The data demonstrate that FBI-1 is a critical regulator
of FASN gene expression not only in the immortalized normal
cells but also in the cancer cells, and it also provides more evi-
FIGURE 3. FBI-1 and SREBP-1a or -1c synergistically activate transcription of pGL2–6x(SRE)-tk*-Luc in
immortalized or cancer cells. A, domain structures of SREBPs and FBI-1. SREBP-1c and SREBP-1a are identical
except N-terminal acidic domain. The bHLH domain are similar among SREBP-1a, -1c, and -2. Acidic, acidic
domain; Pro/Ser, Pro/Ser-rich domain; Ser/Gly/Pro, Gly/Pro/Ser-rich-domain; Gln, Gln-rich domain; bHLH, basic
helix-loop-helix domain; POZ, POZ domain; ZF, Kru¨ppel-like zinc fingers; NLS, nuclear localization sequence.
B, structure of pGL2–6x [SRE]-tk*-Luc plasmid. tk* indicates the thymidine kinase minimal promoter with the
mutations at the two Sp1-binding sites. C–F, FBI-1 enhances transcription activation of the pGL2–6x [SRE]-tk*-
Luc by SREBP-1 in the mammalian cells co-transfected with pGL2–6x [SRE]-tk*-Luc plasmid and expression
vectors of SREBP-1 (25 ng) and FBI-1 (25, 125, and 500 ng). Luciferase activities were normalized with the
protein concentration, and data presented are the average of three independent assays. Bars represent stand-
ard deviations. f, SREBP-1a;, SREBP-1c.
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dence that the interaction between FBI-1 and SREBP-1 is prob-
ably of physiological relevance.
FBI-1 Increases Transcription Activation of FASN Gene by
SREBP-1a—We co-transfected three versions of FASN pro-
moter constructs with the expression vectors of SREBP-1a and
FBI-1 into various mammalian cells such as Alexander,
HEK293A, HCT116, and NIH/3T3 cells to determine which
promoter regulatory elements might be responsive to FBI-1.
The three FASN constructs are different with respect to the
inclusion of Sp1 binding GC-box, SRE, and SRE/E-box ele-
ments. The promoter constructs have been well characterized,
and in previous studies Sp1 and SREBP-1 was shown to syner-
gistically activate transcription by acting on the SRE, GC-box,
and SRE/E-box (34). As expected, SREBP-1a activated tran-
scription of the promoter constructs with the upstream GC-
box and the proximal SRE/E-box. Although FBI-1 alone had
little effect on transcription of any of the promoter constructs,
FBI-1 significantly increased the SREBP-1a-dependent stimu-
lation of transcription of both FASN1 and -2 constructs (Fig. 2,
C–F). The enhancement was particularly effective inHEK293A
and HCT116 cells (Fig. 2, D and E). The FBI-1 was unable to
activate transcription of the FASN3 promoter construct that
lacked the SRE/E-box (Fig. 2, C–F). In NIH/3T3 cells, FBI-1
repressed transcription of FASN3 promoter in a dose-depend-
ent manner in the presence of SREBP-1a (Fig. 2F). The data
suggested that FBI-1 probably stimulates transcription of
FASN promoter bymodulating themolecular events occurring
at the GC-box, SRE/E-box, in cooperation with SREBP-1 and
Sp1.
FBI-1 Synergistically Activates Transcription of the SREBP-1-
responsive Promoter, pGL2–6x(SRE)-Luc, in the Presence of
SREBP-1—Because FBI-1 is expressed in adipocytes and cancer
cells and is correlated with increased lipid accumulation, we
reasoned that itmight directly stimulate expression of lipogenic
genes such as FASN in both cancer derived and immortalized
cells. SREBP-1 is an important regulator of many lipogenic
genes, including FASN. To specifically evaluate whether FBI-1
might target SREBP-1, we prepared a reporter plasmid con-
struct that contains six copies of the well characterized SRE of
the LDLR gene (20) upstream of a minimal tk promoter. The
SRE is essentially identical to that of the upstream SRE (bp
145 to 135) of FASN gene promoter, which is a functional
SRE in adipocytes (28). The SREs were placed just upstream of
themodified tkminimal promoter and luciferase gene (Fig. 3B).
The modified tk minimal promoter contains twomutated Sp1-
binding GC boxes that do not bind Sp1.
We co-transfected the human liver Alexander, human kid-
ney HEK293A, human colon HCT116, and mouse embryo
NIH/3T3 cells with the plasmid mixture of pGL2–6x (SRE)-
tk*-Luc and the expression vectors for SREBP-1a, -1c, and
FBI-1 in various combinations. SREBP-1 alone activated tran-
scription potently as expected. FBI-1 further activated tran-
scription of the promoter by SREBP-1 an additional 2–8-fold
depending on the cell lines tested. FBI-1 alone did not have a
significant effect on the transcription of this promoter (Fig. 3,
C–F). Interestingly, in NIH/3T3 cells, FBI-1 did not affect the
transcription of this test promoter, although SREBP-1 potently
activated transcription as in the other cell lines tested here.
FBI-1 Interacts with SREBP-1 in Vivo—Because FBI-1 and
SREBP-1 synergistically activated transcription of the SREBP-
responsive promoter, we tested if SREBP-1 and FBI-1 might
interact with each other by co-immunoprecipitation. Immuno-
precipitation of the cell lysates prepared from the human
immortalized HEK293A cells and HCT116 colon cancer cells,
using anti-FBI-1 antibody, showed that SREBP-1a forms a com-
plex with FBI-1. Also the immunoprecipitate of the same
extractwith anti-SREBP-1a antibody showed that FBI-1 is pres-
ent in the precipitated complex (Fig. 4A).We also find the same
protein-protein interaction in HCT116 cells (Fig. 4B).
We investigatedwhether FBI-1 and SREBP-1awere co-local-
ized in the nucleus of Alexander cells. The cells were trans-
fected with expression vectors of FLAG-FBI-1, and the mature
form of SREBP-1a was fused with a His tag and analyzed by
immunocytochemistry using anti-FLAG and anti-His antibod-
ies. Transfection of either FBI-1 or SREBP-1a showed both pro-
teinsmainly localized to the nucleus.When cells were co-trans-
fected with the two protein expression vectors and analyzed by
confocal microscopy, both FBI-1 and SREBP-1 were primarily
detected in the nucleus, and the prominent yellow color in the
confocal image suggests there is a molecular interaction
between the two transcription factors in the cell (Fig. 4C).
FIGURE 4. The FBI-1 interacts with SREBP-1a in immortalized human
HEK293A and HCT116 colon cancer cells. A, Western blot (WB) analysis of
co-immunoprecipitates of endogenous FBI-1 and SREBP-1. The HEK293A cell
lysates (500 g) were immunoprecipitated (IP) with anti-FBI-1 antibody and
analyzed by Western blot using an antibody against SREBP-1a. The same
extracts were also immunoprecipitated with anti-SREBP-1a antibody and
analyzed by Western blot using an anti-FBI-1 antibody. B,Western blot anal-
ysis of the co-immunoprecipitates of endogenous FBI-1 and SREBP-1a in
HCT116 cells. The procedures are the same as above. C, immunocytochemis-
try and cellular co-localization of SREBP-1a and FBI-1. The Alexander cells
transfected with the expression vectors of FLAG-FBI-1 and His-tagged
SREBP-1awere analyzedby immunocytochemical stainingusingbothmouse
anti-FLAG antibody and rabbit anti-His antibody. Fluorescein isothiocyanate-
conjugated anti-mouse IgG or rhodamine-conjugated anti-rabbit IgG anti-
body were used as secondary antibodies.
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Zinc Finger DNA Binding Domain of FBI-1 Interacts with the
bHLH Domain of SREBP-1 Directly in Vitro and the ZFDBD of
FBI-1 Increases Transcription Activation by SREBP-1a—
HEK293A cells were transfectedwith the expression vectors for
FLAG-FBI-1 and SREBP-1a-bHLH-Myc (aa 323–394), and the
cell lysates were immunoprecipitated with anti-Myc antibody.
The precipitates were analyzed by Western blotting using an
antibody against FLAG tag. FBI-1 was co-precipitated with the
SREBP-1a-bHLH-Myc fusion protein in vivo (supplement Fig.
2). Because full-length FBI-1 and the bHLH DNA binding
domain of SREBP-1a likely interact in vivo, we investigated
whether the molecular interaction was direct and also which
domain of FBI-1 was interacting with the bHLH of SREBP-1 by
GST fusion protein pulldown assays. The GST-bHLH domain
fusion protein of SREBP-1a was incubated with in vitro synthe-
sized [35S]methionine-labeled FBI-1 and analyzed by a standard
glutathione-agarose pulled down experiment. Autoradiogra-
phy of the SDS-polyacrylamide gel showed that full-length
FBI-1 and the ZFDBD-C-term domain interacted with the
bHLHdomain of SREBP-1. The data suggest that themolecular
interaction is direct and occurs through the DNA binding
domains of each partner protein (Fig. 5B).
To determine whether the ZFDBD domain was sufficient
to stimulate transcription through interaction with
SREBP-1, we investigated whether the ZFDBD of FBI could
increase the transcription of pGL2–6x(SRE)-tk*-Luc pro-
moter by SREBP-1a in two different cell types, Alexander
and HEK293A. The ZFDBD of
FBI-1 increased transcription of
the reporter gene by SREBP-1a,
similar to the full-length FBI-1
protein (Fig. 5C). This result indi-
cates that the ZFDBD domain is
sufficient for both interaction with
and stimulation of transcription
by SREBP-1.
FBI-1 Increases Transcription
Activation ofMuchLonger Promoter
of FASNGene by SREBP-1a—In Fig.
2, we showed that FBI-1 could acti-
vate transcription of the short
FASN promoter (Fig. 2). We also
analyzed transcription of a much
longer promoter element (2.7 kb)
to test whether FBI-1 might also
stimulate transcription of the FASN
gene through other more distal ele-
ments in the promoter. In this
longer construct, mutations were
introduced at the SRE/E-box lo-
cated immediatelydownstreamof the
GC-box to investigate the function of
this key element in the longer pro-
moter context (Fig. 6A). SREBP-
1a was able to activate transcription
of this longer construct strongly as
in the shorter constructs (Fig. 6B).
As in the shorter promoter con-
structs, FBI-1 significantly increased transcription of longer
FASN promoter in HEK293A, HCT116, and NIH/3T3 cells
(Fig. 6, B–D). However, synergistic transcription activation by
SREBP and FBI-1 was not observed with the construct contain-
ing mutations in the proximal SRE/E-box, suggesting that the
proximal SRE/E-box element is essential for the transcriptional
regulation by SREBP-1 and FBI-1 even in the presence of more
distal regulatory elements. However, FBI-1 was not able to
increase the transcription of the longer FASN gene in Alex-
ander and African green monkey kidney CV-1 cells. Rather,
inhibited transcription instead, probably representing cell type-
specific transcriptional regulation of the gene acting either on
the further upstream regulatory sequence or on the proximal
promoter (Fig. 6, E and F).
EMSA Analysis of DNA Binding Activities of FBI-1, Sp1, and
SREBP-1a on GC-box, and SRE/E-box—FBI-1 appeared to
increase transcription of the FASN promoter by modulating
the molecular events occurring at the proximal promoter
region containing the GC-box, and SRE/E-box elements
through the SREBP-1 and Sp1 proteins. Therefore, we investi-
gated themolecular interactions among theDNA elements and
the transcription factors, FBI-1, SREBP-1, and Sp1 using
EMSA.
Sp1 binds to the proximal GC-box of the FASN promoter
and acts as a major activator. Two previous reports showed
that the SREBP-1-binding element and Sp1-binding ele-
ments of FASN and LDLR genes are close to each other and
FIGURE 5. The ZFDBD of FBI-1 interacts with the bHLH domain of SREBP-1a directly in vitro, and the
ZFDBD of FBI-1 is sufficient to activate transcription of SREBP-1-responsive promoter, pGL2–6x(SRE)-
tk*-Luc, by SREBP-1a. A, structures of in vitro translated [35S]methionine-labeled FBI-1 fragments and recom-
binant GST fusion bHLHSREBP-1a used for pulldown assay. bHLH, basic helix-loop-helix domain (aa 323–394);
POZ, POZ domain; ZF, Kru¨ppel-like zinc fingers; NLS, nuclear localization sequence. B, GST fusion protein pull-
down assays. Recombinant GST and GST-bHLHSREBP-1 fusion proteins were incubated with the in vitro syn-
thesized [35S]methionine-labeled FBI-1 polypeptides and then were pulled down. The precipitated samples
were resolvedby12%SDS-PAGEandexposed to x-ray film. Input,10%of the labeledpolypeptides added in the
binding reactions. C, FBI-1 activates transcription of pGL2–6x(SRE)-tk*-Luc by SREBP-1a. The ZFDBD of FBI-1 is
sufficient to activate transcription. Alexander or HEK 293A cells were co-transfected with mixtures of pGL2–
6x(SRE)-tk*-Luc and the expression vectors of SREBP-1a and FBI-1 full-length or the ZFDBD of FBI-1 in various
combinations. Luciferase activities were normalized with the protein concentration, and data presented are
the average of three independent assays. Bars represent standard deviations.f, Alexander cells;, 293A cells.
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can be bound by SREBP and Sp1 simultaneously (28, 34).
Also, recently we and others showed that FBI-1 is also a
GC-box binding transcription factor and can bind some Sp1-
binding GC-box elements (11, 36). The results presented
here show that FBI-1 and SREBP-1a are interacting with
each other via their DNA binding domains (Figs. 4 and 5).
Taken together, the data suggested that the three transcrip-
tion factors may interact with all or parts of the regulatory
elements together on the promoter. Using recombinant ver-
sions of SREBP-1, Sp1, and the ZFDBD of FBI-1, we carried
out EMSA with different FASN promoter fragments to eval-
uate the binding of all three proteins to DNA. The GC-box
and SRE/E-box regulatory elements can be bound by all
three transcription factors (Fig. 7, A and B). The protein-
probe interactions were abolished by the excess cold probes
and also the retarded bands were either supershifted or
abolished by the antibodies specific to the proteins (Fig. 7, C
and D).
FIGURE 6. FBI-1 and SREBP-1a activate transcription of pGL2-FASN-Luc (2.7 kb) via the SRE/E-box elements in immortalized or cancer cells.
A, structures of pGL3-FASN-Luc WT or Mt constructs tested to investigate the functional role of SRE/E-box in transcription activation by FBI-1. SRE,
SREBP-binding element; GC, Sp1-binding GC box; SRE/E-box, downstream SREBP-binding element; Tsp, transcription start site (1). In the mutant FASN
constructs, two SREBP-binding nucleotide sequences of SRE/E-box were mutated by site-directed mutagenesis. B–F, five mammalian cells were co-
transfected with pGL3-FASN-Luc WT or Mt (2.7 kb) and expression vectors of SREBP-1 (25 ng) and FBI-1 (25, 125, and 375 ng) in various combination
indicated. Luciferase activities were normalized with the protein concentration, and data presented are the average of three independent assays. Bars
represent standard deviations.
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Binding competition between SREBP-1a, Sp1, and FBI-1 on
the GC-box and SRE/E-box revealed novel features of binding
interactions on the two key regulatory elements by the three
transcription factors. Although SREBP-1a decreased Sp1 bind-
ing to the GC-box, FBI-1 increased Sp1 binding (Fig. 7E). On
the contrary, on the SRE/E-box probe, FBI-1 decreased
SREBP-1 binding (Fig. 7F). Because of the similar size of the
proteins, it is difficult to analyze the effect of excess Sp1 on the
SREBP-1a binding. Taken together, the data suggested that
interactions among the three transcription factors involves not
only the binding competition but also DNA binding enhance-
ment, which might be important in the transcriptional regula-
tion of FASN gene.
ChIP Assays Showed That FBI-1 Changes the Binding Pattern
of Sp1 and SREBP-1 in the Presence of Induced SREBP-1 and
Drives More Sp1 Binding to the Proximal Promoter Compared
with SREBP-1 Binding—The above data suggested that FBI-1 is
probably increasing transcription of the FASN promoter by
modulating the molecular events
occurring at the proximal GC-box,
SRE/E-box through both SREBP-1
and Sp1. To extend these observa-
tions, we analyzed the protein bind-
ing events on the FASN2, and
FASN3 constructs in HEK293A
cells by a ChIP analysis. The two
constructs are different with respect
to theGC-box, SRE, and SRE/E-box.
FBI-1 activates transcription on the
FASN2 but not on the FASN3 pro-
moter. The promoter constructs
were well characterized previously,
and Sp1 and SREBP-1 were shown
to synergistically activate transcrip-
tion by acting on the GC-box and
the SRE/E-box respectively (34).
In the presence of endogenous
low levels of SREBP-1 and Sp1, Sp1
binding was clearly detectable but
SREBP-1a bindingwas veryweak. In
the presence of overexpressed
SREBP-1a, SREBP-1 binding is
greatly increased, and Sp1 binding is
somewhat decreased (Fig. 8B).
Ectopic FBI-1 bound to the pro-
moter strongly, and inhibited bind-
ing by SREBP-1 and possibly Sp1 as
well. However, Sp1 binding is
increased compared with where
SREBP-1a only was overexpressed,
and the binding pattern is similar to
thatof endogenousSp1andSREBP-1,
although somewhat weaker. This
may explainwhyFBI-1 alone did not
affect transcription of the FASN2
gene (Figs. 2, 3, and 5). When
SREBP-1 and FBI-1 are co-ex-
pressed, binding of both FBI-1 and
SREBP-1 is decreased compared with the situations where the
twoproteins are expressed independently, whereas Sp1 binding
is increased to the level in lane 1 (Fig. 8B, lanes 1 and 4). The
changes in binding pattern either by ectopic FBI-1 or SREBP-1
was not observed in the FASN3 construct, particularly with
respect to Sp1 binding, although FBI-1 might still decrease the
SREBP-1 binding on the upstreamSRE by binding competition.
This binding pattern may be important in the synergistic tran-
scription activation of FASN gene by SREBP-1a and FBI-1.
We also carried out the same set of ChIP assays using the
longer FASN promoter (2.7 kb) constructs. The results were
comparable with the shorter promoter constructs and consist-
ent with the EMSA results. The changes in the transcription
factor binding pattern, which appears to be important for the
increase in transcription, was clearly evident on the wild type
construct but not on the FASN promoter with the mutation at
the SRE/E-box (Fig. 8, C andD). These ChIP and EMSA obser-
vations suggest the activation of FASN by SREBP-1, Sp1, and
FIGURE 7. EMSA of the proximal promoter elements, SRE, GC-box, and SRE/E-box of FASN gene. A, EMSA
of the GC-box probe. The probes were incubated with recombinant SREBP-1 (200 ng), Sp1 (70 ng), and GST-
FBI-1 ZFDBD (150 ng). B, EMSA of the SRE/E-box probe. The probes were incubatedwith recombinant SREBP-1
(20 ng), Sp1 (200 ng), and GST-FBI-1 ZFDBD (150 ng). C and D, EMSA of the GC-box and SRE/E-box probe. Cold
probe competition. E, EMSA. Effect of excess SREBP-1a and FBI-1 proteins on Sp1 binding to theGC-box probe.
The probes were incubated with recombinant Sp1 (50 ng), in the presence of increasing amount of SREBP-1
(200, 600, and 1800 ng) or GST-FBI-1 ZFDBD (150, 450, and 1350 ng). F, EMSA. Effect of excess Sp1 and FBI-1
proteins on SREBP-1a binding to the SRE/E-box probe. The probes were incubated with recombinant SREBP-1
(20 ng), in the presence of increasing amount of Sp1 (200, 600, and 1800 ng), and GST-FBI-1 ZFDBD (150, 450,
and 1350 ng). Arrowheads (‹), retarded protein-probe complexes; arrowheads with star, supershifted probe-
protein-antibody complex. All three recombinant proteins bind to the probes but with different affinity.
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FBI-1 occurs through a mechanism
that is dependent on the combined
interactions between all three
proteins.
DISCUSSION
We initially suspected that FBI-1
might be important in lipid metab-
olism because FBI-1 mRNA expres-
sion was increased in ob/ob
C57BL/6J and DIO mice compared
with the control lean C57BL/6J
mice. Others recently found that
FBI-1 is a potent proto-oncogene
acting at the ARF gene of the p53
pathway (11). FBI-1 caused onco-
genic cellular transformation, and
the transformed cells proliferated
much faster. FBI-1 expression is
often increased in cancer tissues,
and FASN is critical in the cancer
cell proliferation because it is amain
supplier of phospholipid, a critical
component of cell membrane.
FASN gene expression is high in
cancer cells and ismainly controlled
by SREBP-1 and Sp1 (29, 34).
This led us to suspect that there
might be some molecular link
between proto-oncogene FBI-1
and FASN gene expression possi-
bly through effects on SREBP-1.
Indeed, in stable cancer cells
(HCT116) or immortalized stable
cells (293T), overexpression of
FBI-1 resulted in increased FASN
expression. Also, prostate LNCaP
cancer cells treated with andro-
gen, and thus proliferating fast,
showed increased FBI-1 and FASN
expression.
To investigate whether FBI-1
participated in lipid synthesis in
immortalized normal and cancer
cells, we tested transcriptional
regulation of SREBP responsive
genes by transient transfection
assays. FBI-1 activated (2–3-fold)
the transcription of both artificial
and natural SREBP-1-responsive
promoters, such as pGL2–6x-
[SRE]-Luc and FASN gene, in the
presence of SREBP-1. Immuno-
precipitation and GST fusion pro-
tein pulldown showed that
SREBP-1a and FBI-1 interact
directly through their DNA bind-
ing domains, and the interaction is
FIGURE 8. ChIP assays and the molecular binding interaction among FBI-1, SREBP-1, Sp1, and proximal
FASN promoter. A, structures of the pGL2-FASN-Luc reporter promoter constructs tested to study in vivo
transcription factor binding by SREBP-1, FBI-1, and Sp1. B, ChIP assays of the HEK293A cells transfected with
either pGL2-FASN2-Luc or pGL2-FASN3-Luc. C, ChIP assays of the HEK293A cells transfected with pGL3-FASN-
Luc WT or Mt (2.7 kb) plasmid. The HEK293A cells were co-transfected with FASN promoter reporter fusion
plasmid, pcDNA3.1-SREBP-1a and/or pcDNA3-FLAG-FBI-1. Sheared chromatin was immunoprecipitated (IP)
using antibodies indicated. PCR amplification primerswere designed to bind to the plasmid vector sequences,
not to the endogenous FASN gene promoter in case of FASN2 and -3. SRE, SREBP-binding element; GC, Sp1-
bindingGCbox; SRE/E-box, downstreamSREBP-bindingelement; Tsp, transcription start site (1).D,histogram
showing the average of independent ChIP assays shown in C. ChIP binding band intensities by SREBP-1, FBI-1
and Sp1, were divided by input band intensities.
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critical in the synergistic activa-
tion of FASN gene transcription.
To study the regulatory mecha-
nism of FBI-1 on transcriptional
regulation by Sp1 and SREBP-1a on
the FASN promoter, we carried out
a series of transcription analyses,
EMSA and ChIP assays. EMSA
showed that the two key regulatory
elements (GC-box, SRE/E-box)
have unique DNA binding activities
recognizing SREBP-1, Sp1, and
FBI-1. The two elements critical in
transcription activation by FBI-1
and SREBP-1 were bound by all
three transcription factors. The
SRE/E-box is an SREBP-1-binding
element, but it can also be bound
by Sp1 and FBI-1. EMSA showed a
competition between SREBP-1
and FBI-1 on the SRE/E-box. The
EMSA did not provide a clear
result for competition on either
the GC-box or SRE/E-box because
the protein-DNA complexes
migrate to close together; how-
ever, the ChIP experiments sug-
gest a possible binding competi-
tion between Sp1 and SREBP-1 on
the SRE/E-box element.
The previously characterized Sp1
bindingGC-box can also be boundby
SREBP-1 and FBI-1. We recently
found that FBI-1 also binds the SRE
and some GC-boxes of the
p21Waf/Cip1 gene (36, 37). It was
shown previously that DNA binding
activities of SREBP-1 and Sp1 are
overlapping on the two proximal SRE
elements of FASN gene (34) and on
the closely spaced SRE and Sp1
elements of the LDLR promoter
(20). Interestingly, although SREBP-1
decreased the Sp1 binding activity,
FBI-1 increased Sp1 binding on the
GC-box in our studies of the FASN
promoter.
ChIP assay results are basically
consistent with EMSA data in
terms of binding competition and
increases in Sp1 binding by FBI-1.
They also revealed information on
the dynamics of promoter occu-
pancy by FBI-1, SREBP-1a, and
Sp1 on the GC-box, and SRE/E-box
under various conditions. Over-
expression of FBI-1 decreased the
binding activity of SREBP-1 and vice
FIGURE 9. Hypothetical model on the transcription and changes in binding dynamic of three transcrip-
tion factors (FBI-1, Sp1, SREBP-1) on the SRE, GC-box, and SRE/E-box on theproximal promoter of FASN
gene. A, in the control HEK293A cells where Sp1 is abundant and SREBP-1 is uninduced and low, the promoter
elements are mainly bound by Sp1, and transcription is at basal level. No FBI-1 binding is detected. B, upon
induction of SREBP-1, Sp1 binding is significantly reduced, and SREBP-1 binding is high, which resulted in
potent transcription activation. C, upon introduction of FBI-1, Sp1 and SREBP-1 binding are reduced, and FBI-1
binding is high. The binding pattern with respect to Sp1 and SREBP-1 is similar to that of the control, although
at low level. Transcription is at basal level. D, synergistic activation of FASN gene transcription by FBI-1 and
SREBP-1. In the presence of high FBI-1 and SREBP-1, moderate level of SREBP-1 binding and high Sp1 binding
close to the control is achieved. This is probably because of protein interaction between SREBP-1 and FBI-1,
which significantly affects the DNA binding activity of the other protein. Binding by both Sp1 and SREBP-1 of
the promoter in away that favorsmore Sp1over SREBP-1 around theGC-box and the SRE/E-box is important in
synergistic activation of transcription. Transcription is mainly controlled by themolecular interactions among
SRE/E-box,GC-box, FBI-1, Sp1, andSREBP-1.Molecular interactionon theupstreamSRE is alsoexpectedbuthas
no significant effect on transcription activation by FBI-1. Arrows, DNA-protein interactions. Thickness of the
arrow indicated relative binding activity. Tsp (1), transcription start site.
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versa, but there were only minor effects on the binding of Sp1.
When expression of both FBI-1 and SREBP-1 was high and
thus transcription of FASN gene was synergistically acti-
vated, FBI-1 and SREBP-1 binding were significantly
reduced compared with the situation where they were
expressed independently. However, promoter occupancy by
both SREBP-1 and Sp1 is increased, and this DNA binding
pattern favors transcriptional activation. The changes in the
transcription factor binding were probably caused by the
binding competition between SREBP-1 and FBI-1 to the GC-
box and SRE/E-box and also by the protein-protein interac-
tion between SREBP-1 and FBI, via their DNA binding
domains, which could interfere with their DNA binding. The
change in Sp1 and SREBP-1 binding appeared to be primarily
controlled by the SRE/E-box because the binding pattern for
FASN3 and FASN Mt (2.7 kb), where the proximal SRE/E-
box was mutated, was much weaker (Fig. 8, B, lanes 2 and 6,
and C, lanes 2 and 6). The increased transcription factor
binding resulted in 2–3-fold higher FASN gene transcription
compared with conditions where only SREBP-1 was trans-
fected. This situation might reflect robust FASN gene tran-
scription in cancer cells where expression of both FBI-1 and
SREBP-1 is increased.
In summary, we found that the molecular interactions
between the proximalGC-box, SRE/E-box, SREBP-1a, Sp1, and
FBI-1 are important in transcriptional activation of FASN gene
by FBI-1 (Fig. 9). The molecular mechanism of transcription
activation revealed here provides insight into how the proto-
oncogene FBI-1 alters the sensitive cellular regulatory mecha-
nisms of FASN gene expression to provide cellular membrane
components needed for rapid cancer cell proliferation.
FASN, a key multifunctional enzyme of de novo fatty acid syn-
thesis, is highly expressed in most human carcinomas. FASN is
associated with poor prognosis in breast, lung, and prostate can-
cers, and its inhibition is selectively cytotoxic to human cancer
cells. Thus, FASNand fatty acidmetabolism in cancer has become
a focus for the potential diagnosis and treatment of cancer (38).
Because regulating FASNgene expression can be important in the
control of cancer cell growth, the molecular mechanism revealed
here might provide a novel target for the development of future
anti-cancer drugs.
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